Corcept Therapeutics Incorporated
$ 71.20
1.08%
02 Jun - close price
- Market Cap 7,561,846,000 USD
- Current Price $ 71.20
- High / Low $ 71.53 / 68.84
- Stock P/E 201.26
- Book Value 5.94
- EPS 0.35
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE 0.07 %
- 52 Week High 91.00
- 52 Week Low 28.66
About
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
Analyst Target Price
$88.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-24 | 2025-11-04 | 2025-07-31 | 2025-05-05 | 2025-02-26 | 2024-10-30 | 2024-07-29 | 2024-05-01 | 2024-02-15 | 2023-11-01 | 2023-08-02 |
| Reported EPS | -0.3 | 0.2 | 0.16 | 0.29 | 0.17 | 0.26 | 0.41 | 0.32 | 0.25 | 0.28 | 0.28 | 0.25 |
| Estimated EPS | -0.14 | 0.254 | 0.14 | 0.19 | 0.14 | 0.4233 | 0.29 | 0.24 | 0.22 | 0.26 | 0.23 | 0.15 |
| Surprise | -0.16 | -0.054 | 0.02 | 0.1 | 0.03 | -0.1633 | 0.12 | 0.08 | 0.03 | 0.02 | 0.05 | 0.1 |
| Surprise Percentage | -114.2857% | -21.2598% | 14.2857% | 52.6316% | 21.4286% | -38.5778% | 41.3793% | 33.3333% | 13.6364% | 7.6923% | 21.7391% | 66.6667% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CORT
2026-06-02 20:11:09
Corcept Therapeutics CEO Joseph K. Belanoff's trust sold 12,837 shares of CORT stock at $69.74 under a pre-arranged Rule 10b5-1 trading plan. Additionally, the trust made gift transfers totaling 600,000 shares to Grantor Retained Annuity Trusts for estate planning purposes, with no consideration. These transactions are described as routine administrative moves rather than indicators of a change in investment thesis.
2026-06-02 18:11:09
Corcept Therapeutics Inc. (CORT) filed a Form 144 notice indicating a proposed sale of 20,000 shares of common stock associated with a stock option exercise on June 2, 2026, totaling $1,408,800. The filing also detailed several prior dispositions between March and May 2026 by William Guyer, with total proceeds exceeding $2.5 million. Stifel Nicolaus & Company Inc. is listed as the broker for the proposed and past transactions.
2026-06-02 10:11:09
Corcept Therapeutics (CORT) stock has seen a 9-day winning streak, with cumulative gains of 28%, increasing its market cap by $1.6 billion to $7.4 billion. Despite this surge, Trefis evaluates CORT as "Unattractive" due to its moderate operating performance, financial condition, and very high valuation. The article highlights the importance of predictive signals for identifying opportunities before market movements are priced in.
2026-06-01 22:11:09
An insider at Corcept Therapeutics recently sold shares totaling $4,918,944, as disclosed in a recent SEC filing. The article highlights this significant insider transaction, providing details from the official regulatory document.
2026-06-01 22:09:28
Corcept Therapeutics Inc. (NASDAQ: CORT) has filed a Rule 144 notice to sell 160,000 shares of common stock through Stifel Nicolaus & Company Inc. The filing indicates a total amount of $11,200,016.00 and references a Nasdaq listing date of June 1, 2026. This notice also details prior stock option exercises of 95,833 shares on February 2, 2022, and 64,167 shares on February 13, 2023, totaling the 160,000 shares intended for resale.
2026-06-01 15:40:41
Corcept Therapeutics Inc. (CORT) filed a Form 144, indicating proposed sales of common stock by Joseph K. Belanoff. The filing details two recent dispositions by Belanoff: 26,198 shares sold on March 25, 2026, for $1,311,825, and 40,000 shares sold on May 1, 2026, for $2,003,858, totaling 66,198 shares. The document also references a stock option exercise dated July 6, 2022, and names Stifel Nicolaus & Company Inc. as the broker.
